# A Multicenter, Open-label, Randomized Controlled Trial Evaluating the Efficacy and Safety of Romiplostim N01 in the Treatment of Thrombocytopenia Associated With Concurrent/Sequential Chemoradiotherapy and Chemotherapy Combined With/Without Immunotherapy in Solid Tumors

> **NCT07185893** · NA · NOT_YET_RECRUITING · sponsor: **Jun wang** · enrollment: 106 (estimated)

## Conditions studied

- Solid Tumor Malignancies, Cancer
- CTIT-Chemotherapy Induced Thrombocytopenia
- Thrombocytopenia

## Interventions

- **DRUG:** Human Interleukin-11
- **DRUG:** Romiplostim N01

## Key facts

- **NCT ID:** NCT07185893
- **Lead sponsor:** Jun wang
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09
- **Primary completion:** 2028-03-01
- **Final completion:** 2028-12-31
- **Target enrollment:** 106 (ESTIMATED)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07185893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07185893, "A Multicenter, Open-label, Randomized Controlled Trial Evaluating the Efficacy and Safety of Romiplostim N01 in the Treatment of Thrombocytopenia Associated With Concurrent/Sequential Chemoradiotherapy and Chemotherapy Combined With/Without Immunotherapy in Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07185893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*